Davis Todd C
Davis Todd C's purchase track record
How the stock did after each of Davis Todd C's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/11/2026 | PTHS | $1000K | -21.9% | pending | — |
| 5/9/2025 | LGND | $1.00M | +43.6% | +93.8% | +18.9% |
| 8/8/2024 | LGND | $243K | +34.0% | +21.6% | +14.4% |
| 9/22/2023 | LGND | $238K | +21.0% | +20.2% | +21.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Pelthos Expands Coverage for ZELSUVMI Topical Gel. Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.
Transaction History
| LGND | ▼ Sell | Other | 132 | $21K | 6/30/2026 | View on chart |
| PTHS | ▲ Buy | Open Market | 35,445 | $986K | 6/11/2026 | View on chart |
| PTHS | ▲ Buy | Open Market | 503 | $14K | 6/11/2026 | View on chart |
| LGND | ▲ Buy | Grant | 10,495 | $0 | 3/2/2026 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 2,039 | $375K | 2/15/2026 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 4,255 | $782K | 2/15/2026 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 2,805 | $516K | 2/15/2026 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 8,178 | $1.5M | 2/14/2026 | View on chart |
| LGND | ▲ Buy | Grant | 39,644 | $0 | 2/14/2026 | View on chart |
| LGND | ▲ Buy | Grant | 20,782 | $0 | 2/14/2026 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 15,600 | $2.9M | 2/14/2026 | View on chart |
| LGND | ▼ Sell | Gift | 130 | $0 | 12/4/2025 | View on chart |
| PTHS | ▼ Sell | Other | 1,500,000 | $15.0M | 7/1/2025 | View on chart |
| LGND | ▼ Sell | Other | 233 | $21K | 6/30/2025 | View on chart |
| LGND | ▲ Buy | Open Market | 1,680 | $176K | 5/9/2025 | View on chart |
| LGND | ▲ Buy | Open Market | 2,307 | $241K | 5/9/2025 | View on chart |
| LGND | ▲ Buy | Open Market | 5,523 | $584K | 5/9/2025 | View on chart |
| LGND | ▲ Buy | Grant | 21,382 | $0 | 3/4/2025 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 2,231 | $268K | 2/15/2025 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 4,255 | $511K | 2/15/2025 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 6,966 | $836K | 2/14/2025 | View on chart |
| LGND | ▲ Buy | Grant | 20,784 | $0 | 2/14/2025 | View on chart |
| LGND | ▲ Buy | Open Market | 2,500 | $243K | 8/8/2024 | View on chart |
| LGND | ▼ Sell | Other | 350 | $21K | 6/28/2024 | View on chart |
| LGND | ▲ Buy | Option Exercise | 7,448 | $344K | 3/25/2024 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,855 | $192K | 3/25/2024 | View on chart |
| LGND | ▲ Buy | Option Exercise | 2,156 | $148K | 3/25/2024 | View on chart |
| LGND | ▲ Buy | Option Exercise | 3,556 | $235K | 3/25/2024 | View on chart |
| LGND | ▲ Buy | Grant | 32,436 | $0 | 2/27/2024 | View on chart |
| PTHS | ▲ Buy | Option Exercise | 29,167 | $140K | 2/21/2024 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 1,381 | $103K | 2/15/2024 | View on chart |
| LGND | ▲ Buy | Open Market | 4,000 | $238K | 9/22/2023 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 420 | $31K | 6/9/2023 | View on chart |
| LGND | ▲ Buy | Grant | 17,005 | $0 | 2/23/2023 | View on chart |
| LGND | ▲ Buy | Grant | 1,004 | $0 | 6/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript. Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.